UK Rejects Lecanemab for Alzheimer’s: What This Means for Patients
The UK’s NICE has denied NHS coverage for Lecanemab, a drug that slows Alzheimer’s progression by 27% but has modest benefits and serious side effects. Despite approval from the MHRA, the treatment’s high costs and risks, including brain swelling, overshadow its limited impact. This decision leaves many patients to seek the drug privately.